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Abstract 
Introduction  
During the last decade, our institution saw a 260% increase in bilateral breast reconstruction 
cases, consistent with national trends.  We reported a drop in average age of prophylactic 
mastectomy from 57 to 51 years.  There is limited data on the likelihood of histological 
abnormalities in this population.  This study measures the prevalence of occult histological 
findings in prophylactic mastectomy patients.  Given the current healthcare reform climate, we 
estimate the lifetime cost implications of prophylactic mastectomy with immediate 
reconstruction vs. surveillance. 
 
Methods 
A retrospective database of breast reconstructions at the Massachusetts General Hospital was 
searched from 2004 to 2011 for prophylactic mastectomy patients.  Breasts with prior biopsy-
proven LCIS, DCIS, or cancer were excluded.  Patient demographics, risk factors, and pathology 
reports were collected.  Lifetime treatment reimbursements were estimated with 2013 rates from 
the Center for Medicare and Medicaid Services using Medicare billing codes.  Reimbursements 
were estimated for 45-year-old patients undergoing contralateral prophylactic mastectomy and 
40-year-old patients undergoing bilateral prophylactic mastectomies, and then were compared to 
women opting for surveillance. Conversion rates to cancer in these patients were used to estimate 
the percentage patients in the surveillance groups that would need therapeutic mastectomy.  
Sensitivity analyses were done to test the robustness of the models. 
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Results 
495 prophylactic mastectomy specimens were identified, of which 2.0% had invasive cancer, 
4.4% had ductal carcinoma in situ (DCIS), and 10.9% had lobular carcinoma in situ (LCIS) as 
the highest-risk lesion.  Only age group was predictive of finding DCIS or cancer (P=0.02).  The 
likelihood of finding LCIS, DCIS, or cancer increased with age group (P<0.001) and decreased 
with prior bilateral salpingo-oophorectomy (BSO)(P=0.02).  In almost all scenarios, lifetime 
reimbursements were lower for pursuing either contralateral or bilateral prophylactic 
mastectomy, with immediate single-stage implant, expander, or abdominal perforator free flap 
(DIEP) reconstruction, as compared to surveillance. 
 
Conclusions  
Prophylactic mastectomy patients have a significant rate of occult histological findings, 
increasing with age group and decreasing with prior BSO.  Lifetime cost estimates suggest a 
cost-saving role in bilateral and contralateral prophylactic mastectomies.  Ultimately, such a 
critical decision needs to be made individually, but should not be hindered by cost concerns.  
This study addresses a gap in knowledge with broad interest, contributing evidence of oncologic 
risk and cost to help guide decision-making in prophylactic mastectomy. 
 
 
 
 
 
 
  
!! 4!
Table of Contents 
Glossary…………………………………………………………………………………………...5 
Introduction……………………………………………………………………………………….6 
Methods…………………………………………………………………………………………..11 
Results……………………………………………………………………………………………16 
Discussion………………………………………………………………………………………..19 
Summary…………………………………………………………………………………………27 
References………………………………………………………………………………………..28 
Tables and Figures……………………………………………………………………………….37 
  
!! 5!
Glossary 
ASC: ambulatory surgery center 
BMI: body mass index 
BPM: bilateral prophylactic mastectomy 
BSO: bilateral salpingo-oophorectomy 
CPM: contralateral prophylactic mastectomy 
CPT: current procedural terminology 
DCIS: ductal carcinoma in situ 
DRG: diagnosis related group 
HCPCS: Healthcare Common Procedures Coding System 
IPPS: inpatient prospective payment system 
LCIS: lobular carcinoma in situ 
NCCN: National Comprehensive Cancer Network 
OPPS: outpatient prospective payment system 
PM: prophylactic mastectomy 
QALY: quality adjusted life year 
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Introduction  
As observed nationally, our institution has seen a significant increase in the number of 
prophylactic mastectomy (PM) procedures.  Over the last decade, we experienced a 260% 
increase in bilateral breast reconstructions, particularly due to increased application of PM in 
high-risk patients.1 Recent studies have also shown that the number of women opting for 
contralateral prophylactic mastectomy (CPM) is increasing among patients with unilateral breast 
cancer.2  With early studies showing evidence of at least a 90% drop in risk of breast cancer after 
bilateral prophylactic mastectomy (BPM), it is easy to understand why that procedure has 
become more widespread as well.3 Some studies have even estimated a survival advantage after 
the pursuit of PM.4  
Among the subset of high-risk patients are BRCA mutation carriers, who have a 
significant family history of breast or ovarian cancer, and patients with diagnosed cancer in one 
breast who choose to undergo CPM.5 Moreover, patients are also pursuing surgery at a younger 
age, on average 6 years younger at MGH.  BRCA gene status is gradually getting more attention 
in the lay press and PMs have become a common topic of debate.  Women nationwide are 
increasingly considering risk-reducing mastectomies and reconstructions, and are trying to better 
determine what risks they face.  BRCA testing and counseling in itself has been shown to 
increase the rate of women opting for bilateral mastectomy by more than 9 times.6 Concomitant 
with these trends, more women are opting for nipple-sparing mastectomies (NSM) and single-
stage, immediate implant reconstruction whenever possible.7,8 Therefore, more data are 
necessary for women to make informed decisions regarding their options, and for physicians and 
policy-makers to understand the implications of PMs and reconstructions on a national level. 
A recent study by Rai et al. analyzed 301 CPMs, and showed a 2.7% rate of occult cancer 
in the contralateral breast.9 A similar study investigated the rate of occult histology in subareolar 
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biopsies of 80 patients undergoing NSMs to assess the safety of leaving the nipple intact, but did 
not report the histology of the actual mastectomy specimen overall.10 Smaller studies evaluating 
for malignancy in 30 BRCA positive patients undergoing PMs found no cancers, but conclusions 
were limited due to sample size.11 There have been more studies published in the literature, 
which indirectly report on the histological findings of PM specimens, but have not discussed risk 
factors or categorized the findings by patient demographics.  Zhou et al. completed a meta-
analysis of 1343 patients, and among their findings reported a 1.6% chance of invasive cancer 
and a 3.3% rate of DCIS.12-16  Burger and colleagues reported a 1.2% chance of invasive cancer 
and a 3.6% chance of LCIS among 83 PM specimens, but also only as a secondary outcome, and 
with no patient breakdown.17 Evans measured a 3.7% rate of invasive cancer or DCIS.18 One 
study of 107 patients looked for predictive factors of occult histology in CPM specimens, but 
found none.19 There is a need to understand the risk factors that lead to occult histological 
findings, especially with the continually increasing demand for PMs.  Further, given the 
prevalence of genetic screening and the awareness surrounding the diagnosis of BRCA1/2 
mutation carriers, we need a better understanding of the genetics’ role in the timing and 
appropriateness of PM.  
Genetic screening and BRCA diagnoses have only been around since the 1990’s, with 
their use and impact on women’s proactive choices to pursue PMs only more recently becoming 
widespread.  There are even less data on the fiscal impacts the treatment options we choose have 
on lifetime costs of treatment, specifically for breast cancer.20 Since 2004, with the advent of 
immediate breast reconstruction options becoming more popular, mastectomies have also 
become more popular, particularly PMs.21 In the last decade, nipple-sparing mastectomies and 
direct-to-implant (also known as “single-stage implant”) immediate reconstructions have also 
become increasingly popular, adding to the reconstructive repertoire, and gaining in use 
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particularly within the PM patient population.  In this study, we estimate the lifetime 
reimbursements of high-risk women choosing to start with either surveillance of at-risk breasts 
or proceed to prophylactic mastectomy, and modeling the different possibilities of immediate 
reconstruction.  Moreover, given the dearth of data comparing the lifetime costs of choosing 
surveillance or prophylactic mastectomy with immediate reconstruction, estimating the economic 
impacts of these choices are critical to understanding the fiscal implications on a national level.  
Specifically, it is important understand the influence of both BPMs and CPMs.  To date, all but 
one of the studies that have evaluated the costs of risk reduction focused on BPMs instead of 
CPMs. 
Anderson and colleagues completed a cost-utility analysis comparing different 
surveillance and preventive strategies in BRCA gene carriers, estimating that the most cost-
effective approach was PM with bilateral salpingo-oophorectomy (BSO), increasing in cost-
effectiveness the younger the patient was, and costing as little as $100 per quality-adjusted life 
year (QALY) gained.22 However, endometrial cancer, pulmonary emboli, and cataracts were the 
only complications included in the model.  The costs of reconstructive options were not included.  
The standard threshold used to decide whether a treatment is cost-effective is $50,000/QALY, 
meaning anything below that is considered a worthwhile investment. Therefore, $100/QALY is a 
bargain.  Another study estimated that PM and BSO had a survival advantage, and in the highest-
risk patients, also led to QALY gains.4 According to its estimates, PM was up to an additional 
$1,277/QALY, still well within range of cost-effectiveness.  A follow-up study by Grann 
estimated that BPM and BSO were both less expensive throughout a patient’s life than starting 
with tamoxifen treatment or regular surveillance, sometimes more than an estimated $40,000 in 
savings throughout a patient’s lifetime.23 Although the study did estimate a contribution to 
overall patient survival, its estimates suggested a slight drop in quality of life.  Lastly, a 
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Norwegian study estimated cost savings in pursuing prophylactic BSO and BPM, especially after 
including the productivity gains and indirect costs associated with long-term gains, as well as an 
increase in life expectancy based on its model of BPM at age 30 and BSO at 35.24  
 The cost of CPMs has also been estimated, and was also found to be cost-effective in 
comparison to surveillance.  One study evaluated the cost-utility of 45 year old women 
undergoing CPM in the setting of unilateral breast cancer, comparing it to surveillance, and 
including the likelihood of recurrences and further treatments.25 Slightly more expensive than 
surveillance, CPM led to an increase in QALYs and a cost-effectiveness ratio of $4,869/QALY, 
again well below the $50,000/QALY threshold.  However, this study, just like all of the cost 
estimates of BPM mentioned previously, did not take into account reconstructive choices made 
by the patients and the likely complications, revision rates, and follow-up associated with each of 
those choices.  Especially since the passing of the Women’s Health and Cancer Right’s Act of 
1998, which established that insurers must cover the breast reconstructions of women who 
undergo mastectomy, it is critical to understand not only the impact of mastectomy trends, but 
also their associated reconstructions.26 
 This study aims to address the question of whether we, both individually and as a society, 
should continue to increasingly pursue PMs by evaluating two components: histology and 
lifetime cost. First, what is the rate of occult histological findings in high-risk women pursuing 
BPMs or CPMs, and are there discernable predictive factors? Second, what are the lifetime 
financial implications of these findings as more women continue to opt for risk reduction? Given 
the many reconstructive choices patients have to choose from, the latter question must be 
answered with an understanding of the impact each reconstructive method has on lifetime 
treatment costs.  We hypothesize that the rate of occult histological findings is greater in the 
high-risk patient population, possibly highest in BRCA positive patients, given their higher 
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cumulative lifetime risk of breast cancer.  Additionally, the increased initial costs of prophylactic 
mastectomy may balance with overall savings in breast cancer treatments further in life, leading 
to overall cost-savings even after factoring in the reconstruction costs.  If so, we hope that our 
findings will guide us to make more informed decisions about the best courses of action. 
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Methods 
Study subjects 
This retrospective study is based on patients treated at a tertiary academic medical center 
between 2004 and 2011.  It was reviewed and approved by the Massachusetts General Hospital 
(MGH) Institutional Review Board.  Surgeons involved in the cases were from the Gillette 
Center for Breast Cancer and the Division of Plastic and Reconstructive Surgery at MGH.  A 
prospectively-maintained database of implant breast reconstructions was used to identify patients 
undergoing mastectomies on both breasts.  No comparable autologous-based reconstruction 
database was available, so those patients were not included in this study.  Inclusion criteria were 
having a listed indication of prophylactic mastectomy in one or both breasts and having the 
mastectomy specimens’ pathology available in the patient’s electronic medical record.  
Prophylactic mastectomy in this study is defined as mastectomy of a breast that has not had a 
prior biopsy suggestive of cancer.  Patients with prior biopsy of findings of lobular carcinoma in 
situ (LCIS), ductal carcinoma in situ (DCIS), or carcinoma in the breast(s) considered 
prophylactic were excluded from the study.  Preoperative imaging was not necessary for 
inclusion. 
 
Data retrieval 
Using each patient’s medical record number, the following variables were collected: age, 
BMI, history of smoking, radiation, chemotherapy, and bilateral salpingo-oophorectomy (BSO), 
BRCA status, family history of breast or ovarian cancer, number of breasts treated with 
prophylactic mastectomy.  The most concerning lesion for each prophylactic mastectomy 
specimen was noted (in order: normal, atypia, LCIS, DCIS, carcinoma).  Age group for each 
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patient was determined by the patient’s decade of life (age 20-29, 30-39, 40-49, 50-59, 60-69, 
70+). 
 
Statistical analyses 
Data were analyzed using STATA 12.1 for Mac (StataCorp, College Station, TX), using 
p-value < 0.05 as statistically significant.  Univariate analyses were conducted with a chi-squared 
test to determine differences between groups, and Fisher’s exact test was used to compare groups 
with outcome samples too small for chi-squared tests.  2-sided student t-test with equal variance 
but unequal sample size was used for comparing continuous variables in patient demographics.  
A final multivariate logistic regression model was used to measure the significance of a change 
in one variable while adjusting for the effects of the other variables. 
 
Reimbursements 
Physician, anesthesia, hospital, and ambulatory surgery center reimbursements were used 
to estimate the lifetime reimbursements per patient of choosing surveillance or PM.  After 
therapeutic or prophylactic mastectomy, all patients were modeled to receive immediate breast 
reconstruction, with one of three reconstructive choices: single-stage direct-to-implant, two-stage 
expander to implant reconstruction, and abdominal perforator free flap reconstruction.  These 
were considered for women considering CPM or BPM.  Reimbursements for 12 groups in total 
were estimated (Table 1).  For patients 1a-1f, reimbursements summed were those in addition to 
the expected reimbursements necessary for the treatment of their already-diagnosed unilateral 
breast cancers.  Physician reimbursements for each procedure were estimated using Medicare’s 
2013 fee schedules, using Current Procedural Terminology (CPT) and Healthcare Common 
Procedures Coding System (HCPCS) codes to look up relevant reimbursements.27 CPT and 
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HCPCS codes were also used to look up reimbursements for separate supplies, such as acellular 
dermal matrix (ADM) and implants.  The national index reimbursement level was used.  
Anesthesia reimbursement rates were estimated using base units, time units, and the 2013 
conversion factor ($21.92). Reimbursement rate was estimated with the formula: 2013 
conversion factor x (base units + time units).  Hospital reimbursements were based on the Acute 
Care Hospital Inpatient Prospective Payment System (IPPS) using relevant Diagnosis Related 
Group (DRG) codes.  Each reimbursement is based on the 2013 Federal Operating Base Payment 
Rate ($5,348.76), 2013 Federal Capital Base Payment Rate ($425.49), and the DRG Relative 
Weights for each hospital admission.28 Each DRG encapsulates a group of hospitalizations 
expected to have a similar resource use and equal reimbursement.29  Follow-up procedures that 
are appropriate to do in an ambulatory surgery center (ASC) were modeled using the Outpatient 
Prospective Payment System (OPPS) that covers all of the facility costs through a bundled ASC 
payment rate.30  Payment rates from January 2013 were used.31  The billing codes used are listed 
in Table 2.  Given the variability in how radiation therapy and chemotherapy are applied, and 
how billing is done depends on the treatment and methods of application, the costs of radiation 
and chemotherapy used were based on prior estimates in the literature.32 Indirect costs on society 
and productivity were not included.  Terminal costs of health care for patients at the end of life 
were not estimated. 
 
Models 
Decision tree models were built for all groups.  For groups choosing surveillance, the 
probability of each patient developing breast cancer was based on age-dependent probabilities 
for each patient subtype in the literature.25,33  Specifically, it was for patients with a prior history 
of breast cancer undergoing surveillance of the contralateral breast, or BRCA carriers with no 
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prior history of breast cancer in either breast.  Decision trees spanned 30 years at 5-year intervals 
(Figure 1).  Patients opting for PMs were assumed to undergo surgery at the beginning age of 
their respective models.  The National Comprehensive Cancer Network (NCCN) breast cancer 
guidelines were used to model surveillance, preoperative testing, treatments, and post-operative 
follow-up.34-36  For situations without established guidelines, the standard of care at MGH was 
used.  Modeling of operative revisions, nipple-areola complex (NAC) reconstruction, and 
implant exchanges throughout the 30 year period were included (Tables 3a and 3b).37-40  The 
costs and frequency of biopsies, imaging when indicated, and further mammographic screening 
were also considered.  Rates of radiation and chemotherapy use for each patient situation were 
estimated from the patient demographics presented in this study.  Estimates for cost of 
neoadjuvant and adjuvant chemotherapy was assumed to be the same, although the percentage 
receiving each type differed for each group. 
Reimbursements are presented in 2013 U.S. Dollars ($).  The Medical Care Services 
Index, a component of the Consumer Price Index that includes professional health services and 
hospital services, was used to estimate the yearly growth in reimbursements.  Reimbursements 
were adjusted for inflation.41  The yearly inflation-adjusted increase in the Medical Care Services 
Index averaged 1.63% over from 2003-2013, so an estimate of 1.5% was used for baseline 
models.42  A 3% discount rate was applied to calculate the present value of reimbursements over 
30 years. 
 
Sensitivity analyses 
The yearly inflation-adjusted growth in reimbursement rates was varied from 0-3%, given 
the variability in inflation from year to year.  The discount rate was varied from 0-7%, based on 
the standard set by the Recommendations from the Panel on Cost-Effectiveness in Health and 
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Medicine.43 Additionally, another sensitivity analysis was done that simultaneously varied all of 
the inputs that could significantly lower the price of surveillance vs. PM, in order to fully 
ascertain the robustness of the models, even in the most stringent of scenarios.  
 
 
 
 
 
  
!! 16!
Results 
Histology 
Patients who underwent a BPM were more likely to be BRCA positive, have a family 
history, and have a prior BSO.  Of note, BRCA positive patients were found to have undergone a 
BSO more frequently (42% vs. 7%, p-value <0.001) and to have been 2 years younger on 
average (43.2 vs. 45.2, p-value=0.017).  Those who underwent a CPM were more likely to 
undergo chemotherapy and radiation (Table 4).  Overall, 10 (2.0%) of the PM specimens had 
cancer, 22 (4.4%) had DCIS, 54 (10.9%) had LCIS, and 104 (21.0%) had atypia as the highest 
risk lesion.  In univariate analyses, the likelihood of malignant pathology (DCIS or cancer) per 
specimen only significantly increased with each decade life in CPM patients (P-value = 0.020), 
but otherwise was unaffected by any of the measured variables (Table 5). Meanwhile, abnormal 
pathology (LCIS, DCIS, or cancer) per specimen increased even more significantly with each 
decade of life (P-value < 0.001), rising from 0% in patients under 30 years old to 37% in patients 
older than 60 years of age (Figure 2). Abnormal pathology was more likely in specimens of 
BRCA negative patients (22.2%) than in those of BRCA positive patients (8.9%, P-value = 
0.019).  Specimens of patients with prior BSOs less frequently had abnormal pathology than 
those without (7.7% vs. 19.9%, P-value = 0.003).  Family history, BMI ≥ 30, smoking history, 
and chemotherapy did not have statistically significant impacts on the rate of histological 
findings in univariate analysis.  A summary of the abnormal pathology findings is presented in 
Table 6.  A multivariate logistic regression confirmed age group to be independently predictive 
of malignant pathology in each specimen, while age group and preoperative BSO status were 
both independent predictors of abnormal pathology when controlling for other variables (Table 
7).   
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Lifetime reimbursements 
Among patients with unilateral breast cancer, those who underwent CPM at the time of 
therapeutic mastectomy added significantly less to the estimated reimbursements than those who 
chose surveillance.  Specifically, among patients who chose implant, expander, and abdominal 
perforator free flap (DIEP: Deep Inferior Epigastric Perforator) reconstruction after PM, the 
baseline model estimated lifetime savings of $7,017 (Group 1d – 1a), $7,101 (Group 1e – 1b), 
and $7,495 (Group 1f – 1c), respectively.   
For BRCA positive patients considering BPM, patients choosing BPM usually spent less 
than those choosing surveillance, except for patients opting for expander-based reconstruction 
(Group 2b vs. 2e).  Specifically, patients opting for prophylactic mastectomies spent $1,231 less 
if they underwent single-stage implant reconstruction (Group 2d vs. 2a) and $7,391 less if they 
underwent immediate DIEP reconstruction (Group 2f vs. 2c).  However, those opting for 
expander-based reconstruction after prophylactic mastectomy spent an estimated $109 more than 
patients choosing surveillance (Group 2e vs. 2b). 
 
Sensitivity analyses 
 Sensitivity analyses were conducted first by varying inflation-adjusted growth rates from 
0-3% and discount rates from 0-7%.  Those sensitivity analyses are presented in Table 8a for 
CPM patients and in Table 8b for BPM patients.  Additionally, we also conducted a sensitivity 
analysis each for CPM and BPM patients by varying the inputs that were most likely to have 
significant impacts on the lifetime reimbursements of surveillance and prophylactic 
mastectomies.  After changing certain baseline assumptions in Tables 3a and 3b simultaneously, 
which are detailed under the “sensitivity analysis” columns, CPM was still cost-saving across all 
three reconstructive choices.  Specifically, it would save an estimated $6,875 for single-stage 
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implant reconstruction, $6,958 for expander reconstruction, and $7,305 for DIEP reconstruction.  
For BPM, only DIEP reconstruction remained cost-saving at an estimated $5,826 less than 
surveillance.  For single-stage implant and expander-based reconstructions, prophylactic 
mastectomy would cost $841 and $2,137 more than surveillance, respectively. 
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Discussion  
As the frequency of contralateral and bilateral PMs continue to increase, women are 
seeking more proactive approaches to risk reduction.  There has even been a 50% increase in the 
rate of BPM for women with LCIS, with 16% of them opting for BPM in 2009.44 More 
information was needed regarding the occult histology in these patients’ breasts, and an 
understanding of the trend’s impact on lifetime costs of treatment was warranted.  This study 
addressed both.  Specifically different from prior studies were the findings of predictive factors 
of histology, the inclusion of reconstruction costs throughout the patient’s lifetime, and including 
three different reconstruction methods.  Our results suggest that this patient population has a 
significant rate of occult histological findings and that prophylactic mastectomies with 
immediate reconstructions have a cost-saving role in most scenarios. 
The rate of occult histological findings in both CPM and BPM patients was high, as 
hypothesized given the lifetime incidence of cancer in BRCA positive patients and high-risk 
patients with a prior history of unilateral breast cancer.  We found that 6.5% of the breast 
specimens had DCIS or cancer, as compared to 0.3-1.0% in studies of reduction mammoplasty 
specimens.45-48  Meanwhile, the rate increased to 17.4% when including LCIS, compared to 0.4-
1.3% in reduction mammoplasty specimens of the same studies, representing at least a 13-fold 
increased risk in our sample. The results are in line with our original histological hypothesis.  
Our CPM results are similar to a smaller study of 301 patients, with malignant pathology in 4.3% 
of specimens, slightly lower than our 6.9%.9 Given our larger sample size, the actual prevalence 
may be closer to our 6.9%. A study with 239 patients found 7.9% had abnormal pathology in 
contralateral specimens, significantly lower than our 19.4%, and possibly indicative of slightly 
higher risk patients in our sample.49 Particularly surprising was the 0.586 odds ratio of abnormal 
pathology in specimens of BRCA positive patients even after adjusting for other variables.  The 
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p-value of 0.122 suggests that perhaps a larger sample size would find statistical significance, but 
our data are not sufficient to suggest a difference in the prevalence of findings in BRCA positive 
patients.  BRCA patients’ abnormal pathology prevalence in smaller studies has ranged from 
3.4% to 10%.50,51 However, the patients in those studies were younger on average, which may 
explain their findings’ discrepancy with our 12.3%. The findings that prior BSO and younger age 
reduce abnormal pathology are consistent with previously published data. 
 The rate of LCIS was important to consider given the 8-10 fold increased risk of cancer 
in these patients.52 In addition, the National Cancer Institute recognizes BPM as a treatment 
option for these patients, and younger women have been shown to more commonly pursue BPM 
when diagnosed with LCIS.44,53  Therefore, given the increasing trend of risk-reduction through 
PM, especially in younger patients, we believe the inclusion of LCIS to be relevant to the debate.  
Nonetheless, some experts consider BPM too drastic, and instead recommend surveillance with 
annual mammograms or chemoprevention with tamoxifen, which decreases the risk of cancer in 
LCIS patients by 56%.34,54  For that reason, we also analyzed malignant pathology separately. 
 The models suggest that CPMs and BPMs often have a cost-saving role when comparing 
surveillance versus prophylaxis within the same reconstructive choice (single-stage implant, 
expander, or DIEP).  The only exception is BPM with expander-based reconstruction, which was 
only $109 more expensive.  For unilateral breast cancer patients, opting for CPM at the time of 
therapeutic mastectomy was cost-saving in all scenarios.  The savings occur because most of the 
necessary testing, office visits, and hospitalizations, and follow-up costs would be done at the 
same time as treatment for the cancerous breast.  Moreover, many of the treatment and follow-up 
costs, such as screening MRI’s, have reimbursements that are barely affected by whether the 
service is unilateral or bilateral, meaning many of the reimbursements would have been rewarded 
similarly even if only the therapeutic mastectomy had been done.  Opting for surveillance will 
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potentially require additional hospitalizations, anesthesia, and operations at times that would not 
overlap with the therapeutic mastectomy, and thus add significant costs to the original expenses 
of treating unilateral breast cancer. 
 The models for patients considering BPM were closer in lifetime reimbursement costs.  
The total inflation-adjusted reimbursements of choosing prophylaxis was $1,231 less than 
surveillance with implant reconstruction, and $7,391 less for DIEP reconstructions.  These 
estimates include the 3% discount rate over the 30-year period, which helps to capture the real 
dollar value over the period of time by taking into account the time-value of money.  These 
estimates reinforce the belief that women who desire risk-reducing mastectomies with immediate 
reconstruction should be covered by insurance and Medicare, because they are estimated to save 
money in the long run.  The up front costs of having all interested women pursue PMs balance 
out by diminishing the need for future MRI’s, mammograms, biopsies, and the higher costs of 
treatment of therapeutic mastectomies, especially because more of those women undergo 
chemotherapy and radiation.  Moreover, opting for PM increases the likelihood of being a 
candidate for NSM, which has been shown to increase patient satisfaction due to improved 
aesthetic result.10,40,55  Younger patients after BPM rarely need radiation and chemotherapy, 
further improving the aesthetic outcomes and diminishing the likelihood of complications.56 Not 
all changes are beneficial.  For example, although risk-reducing mastectomy and reconstruction 
leave most women satisfied with their breast sizes, nearly half of them think their reconstructed 
breasts were too hard.57  These considerations are equally important for patients to be aware of, 
as the more informed women are about their options and the more empowered they feel to 
choose the option they consider most appropriate, the higher the likelihood that they will be 
satisfied.  Our results are consistent with the prior studies that showed incremental cost-
effectiveness of prophylactic mastectomy over other preventive strategies.22 Our estimates go 
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further by also estimating the cost of reconstructions, both immediately and of future revisions 
that patients will likely require or desire in their lifetimes.   
The strengths of this research should be broken down into the histological analysis and 
the lifetime reimbursement estimates.  To our knowledge, this is the first study of this size to 
identify predictive factors of occult histology in BRCA women.  Additionally, the inclusion of 
CPM women without BRCA expands the patient population considered and allows us to better 
compare to other studies who have also studied occult histology in CPM patients.  After 
identifying likely predictive factors through a univariate analysis, the variables were further 
analyzed in a multivariate analysis, which helped solidify the identification of younger age and 
prior BSO as predictive factors of a lower likelihood of occult histology.   For the estimates of 
lifetime reimbursements, this is the first study to analyze the impacts of the different 
reconstructive options on the estimated costs of treating a patient long-term.  With immediate 
reconstructions becoming more popular, the modeling of three immediate reconstruction choices 
adds to the versatility of this study, assuring physicians that PM can be cost-effective despite of 
the reconstructive method used, and improving the ability of surgical oncologists and plastic 
surgeons to make more informed decisions.  Moreover, both CPM and BPM patients were 
modeled.   
Sensitivity analyses were completed for both CPM and BPM patients to test the 
robustness of the models and the lifetime reimbursement estimates.  One set of sensitivity 
analysis was done by varying economic situations by changing the inflation-adjusted growth rate 
and the discount rate.  For these scenarios, which are included in Tables 8a and 8b, although the 
absolute value estimates of reimbursements changed significantly for each of the scenarios, in a 
majority of them CPM and BPM continued to be more cost-effective throughout the patients’ 
lifetimes than surveillance.  The results of that sensitivity analysis suggest that despite whatever 
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economic realities the United States faces in the next 30 years, chances are that PMs will 
continue to be cost-effective.  Moreover, we also decided to conduct a sensitivity analysis by 
varying the inputs that could favorably reduce the cost of surveillance relative to PM.  By 
changing all of those inputs at once, as presented in Tables 3a and 3b, we measured the impact 
they could have on our lifetime reimbursement estimates.  Despite changing all of the variables 
to a more favorable position for surveillance, the impacts were minimal across all of the models.  
All of the CPM models remained cost-saving, and only the single-stage implant reconstruction 
model after BPM became more expensive than surveillance, although only by $841, which is a 
small difference when spread out over a patient’s lifetime.  Expander-based reconstruction 
remained slightly more expensive also after BPM, but also did not change significantly from the 
original model.  These sensitivity analyses suggest that in many scenarios, despite changing 
assumptions, PMs continue to be cost-effective. 
Limitations of the study should also be broken down into histological analysis and 
reimbursement estimates.  One limitation of the histological analysis is that preoperative 
radiological findings were not evaluated.  Some studies have excluded patients with concerning 
mammogram or MRI findings, but to maximize sample size, we did not require preoperative 
imaging for inclusion.  Some patients could potentially have been excluded with radiological 
findings, which could make our findings slightly higher than they would be in if all patients were 
confirmed to be radiologically-negative.  In contrast, a small percent of women have neoplastic 
cells in their nipples, so the higher proportion of NSMs at our institution may lead to an 
underestimation of the prevalence of occult histology.8 Additionally, MGH is a referral center for 
many complex patients.  Therefore, the high-risk patients requesting prophylactic mastectomies 
at MGH may be more likely to have occult histology than the high-risk patients pursuing surgery 
elsewhere, as those with really high risk may be seeking out more advanced centers, such as 
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MGH. Yet another histological limitation is that the study size did not have the power to detect 
differences between BRCA and non-BRCA carriers during multivariate analysis.  Finally, this 
study did not measure the occult histology in patients undergoing autologous breast 
reconstruction, as an equivalent database was not available.  While the occult histological 
findings are likely similar in that patient population, it is possible that those patients have higher 
BMI’s on average, and slightly different histological findings.  Therefore, the findings in our 
patient population must be extrapolated to those patients with caution. 
The modeling of lifetime reimbursements also has its limitations in what is included, how 
it is coded, variability in reimbursement, and accuracy in literature predictions.  As in all models, 
ours are also a reduced representation of reality, meaning that every reimbursement that is billed 
in real life is not included in our models.  For example, our models do not include the terminal 
costs at the end of life, the gradual passing away of more patients in the surveillance models than 
in the PM models, the indirect costs of care (e.g. productivity costs), or the follow up treatment 
costs incurred after post-operative biopsies diagnose patients with a recurrence of cancer.  If 
surveillance patients were on average to die 10 years earlier, and had similar terminal life costs 
as PM patients, then their limited life expectancy would potentially incur less costs on the health 
care system, but with a reduced lifespan.  Another limitation surrounds the coding of treatments, 
which are simplified in our models out of necessity.  For example, a patient undergoing a 
revision after an autologous free flap reconstruction may be undergoing revisions of the breasts 
or donor site, and may be undergoing everything from liposuction and removal of dog-ears to the 
placement of expanders after the failure of a free flap.  These procedures would all be billed 
differently, yet given the difficulty in accurately predicting all of those different possibilities 
throughout different patient populations, simplification of coding for revisions is necessary.  
Furthermore, these models apply a national index reimbursement rate for Medicare payments, to 
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keep the applicability as broad as possible, but in reality reimbursement varies by location within 
Medicare, and even more significantly for private insurers. However, since many insurance 
companies rely on the standards set by Medicare to establish their own reimbursement patterns, 
although their reimbursements are typically higher in value, they are likely proportional to the 
Medicare distributions.  Therefore the cost-savings should still be present, although possibly on a 
higher scale.  Similarly, we are measuring reimbursements, as they inform the national impact, 
but do not necessarily reflect the true resource costs of providing these services. 
The final category of limitations is the published literature.  The success of the models is 
largely dependent on the accuracy of the assumptions made based on the plastic surgery 
literature, including everything from the percent of patients receiving radiation to the percent of 
patients with implants undergoing revisions or explants every year.  Two main examples are the 
cancer incidence rates by age for contralateral cancer in unilateral breast cancer patients and 
primary cancer in BRCA positive patients. These rates were used to predict the percentage of 
patients starting with surveillance that would ultimately require a therapeutic mastectomy.  
Another limitation of the published literature for making estimates through models is the 
granularity of data.  For example, to make the best possible predictions, one needs studies that 
can show the difference in reoperations, if any, between unilateral and bilateral breast 
reconstructions, between radiation effects in patients who have single-stage implant 
reconstructions, expander-based reconstructions, and autologous reconstructions.  Data for all 
possible scenarios used in our model were not available. For example, we were unable to find 
useful data on what percentage of patients undergoing sentinel lymph node biopsies ultimately 
also require an axillary dissection, so we simply modeled it with 10% for most models.  For the 
revisions of unilateral and bilateral procedures, we assumed the revision rate per patient to be the 
same because we did not find reliable data on the differences between the two, and because 
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many unilateral patients ultimately undergo symmetrization procedures, so for simplification we 
assumed the rates to be the same as for patients who underwent bilateral reconstructions.  Using 
the same logic, we made the assumption for modeling purposes that women who underwent 
CPM would ultimately have revisions at the same time that they needed to for their original 
breast cancers, and therefore were part of the same procedures and hospitalizations.  However, it 
is reassuring that throughout the sensitivity analyses for all patient groups, most scenarios 
remained cost-saving for women choosing PM.  The cost estimates are also limited to women 
undergoing immediate breast reconstruction, and therefore may not be applicable to women 
undergoing delayed breast reconstructions.  
Future studies evaluating occult histological findings in this PM patients should further 
investigate the possibility that BRCA patients may have a lower rate of abnormal pathology as 
opposed to non-BRCA patients seeking PM.  A larger sample size than ours would be needed to 
evaluate BRCA gene carrier status within a multivariate analysis.  For estimating costs, it would 
be best to reflect on the actual billing patterns over a 15-20 year period for these patients.  What 
did the hospitals and physicians bill? How much money related to breast cancer or prevention 
was rewarded?  Actual data, as opposed to predictions based on literature estimates of revisions, 
cancer incidence, etc. would provide more useful data, but is still a few years away, as BRCA 
testing and the immediate reconstructions modeled in this study have not been around long-
enough to measure actual costs. 
In 2011, there were an estimated 288,130 breast cancer cases in the U.S.  If those patients 
had all undergone a CPM, the nationwide lifetime savings would be worth slightly more than $2 
billion.58 Meanwhile, an estimated 1% of the general population has the BRCA mutation.59 If an 
estimated 150 million women live in the U.S., about 1.5 million are BRCA mutation carriers, 
with about 20,000 women per year turning 40 with a BRCA diagnosis.  If all of those patients 
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underwent BPM with either single-stage implant reconstruction or DIEP reconstruction, the 
savings per year would be anywhere between $24 million to over $147 million.   
 
Summary  
This study lends support for decisions of CPM and BPM as options that are not only 
appropriate for high-risk patients who want risk-reduction, but are also cost-saving long-term.  
As costs continue to constrain healthcare delivery, we can rest assured that these procedures are 
not worsening the cost-burden on our society.  Moreover, the significant findings of abnormal 
pathology clearly suggest that these high-risk patients pursuing PM are at a significantly higher 
risk of developing cancer than the general population.  Nonetheless, this remains a very difficult 
and personal decision for many women, as it has many physical and psychological implications, 
and can only be appropriately weighed by each individual patient with the support of her friends, 
family, and physicians.   
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Tables and Figures 
 
Table 1 
 Group designations 
Unilateral breast cancer patients considering CPM 
1a Surveillance, implant reconstruction 
1b Surveillance, expander reconstruction 
1c Surveillance, DIEP reconstruction 
1d Prophylaxis, implant reconstruction 
1e Prophylaxis, expander reconstruction 
1f Prophylaxis, DIEP reconstruction 
BRCA patients considering BPM 
2a Surveillance, implant reconstruction 
2b Surveillance, expander reconstruction 
2c Surveillance, DIEP reconstruction 
2d Prophylaxis, implant reconstruction 
2e Prophylaxis, expander reconstruction 
2f Prophylaxis, DIEP reconstruction 
Note: Surveillance groups list the type of reconstruction that the patients requiring 
therapeutic mastectomies would ultimately have. 
 ! !
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Table 2   
Billing codes used for cost modeling   
Surveillance and Follow-up 
CPT/HCPCS 
Code 
Office visit 99214 
Computer aided detection with physician review; diagnostic 77051 
computer aided detection with physician review of mammogram 77052 
Mammography, unilateral 77055 
mammography, bilateral 77056 
screening mammography, bilateral, 2 view film study of each breast 77057 
unilateral breast MRI 77058 
bilateral breast MRI 77059 
    
Work-Up 
CPT/HCPCS 
Code 
Breast biopsy, needle core, using imaging guidance 19102 
Breast biopsy, automated vacuum assisted device, with imaging guidance 19103 
placement of percutaneous localization clip 19295 
MRI guidance for needle placement, radiological supervision and 
interpretation 77021 
Mammographic guidance for needle placement, radiological supervision and 
interpretation 77032 
Level IV- surgical pathology, gross and microscopic exam (breast biopsy) 88305 
Level V-surgical pathology exam (mastectomy) 88307 
Level VI-surgical pathology exam (breast mastectomy with regional nodes) 88309 
Immunohistochemistry (for each antibody) 88342 
Comprehensive metabolic panel 80053 
CBC, automated, and differential WBC count 85025 
    
Imaging 
CPT/HCPCS 
Code 
Chest CT 71260 
Abdominal/pelvic CT 74177 
Bone scan (tomographic SPECT) 78320 
    
Surgery 
CPT/HCPCS 
Code 
Alloderm unilateral 15777 
Mastectomy 19304 
Immediate insertion of breast prosthesis in reconstruction 19340 
Delayed insertion of prosthesis in breast reconstruction 19342 
Nipple reconstruction 19350 
Breast reconstruction with TE, including subsequent expansion 19357 
Breast reconstruction with free flap 19364 
Revision of reconstructed breast 19380 
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Lymphangiography for node identification 38792 
Biopsy or excision of nodes 38525 
Axillary node dissection 38745 
Implant L8600 
Replacement of expander with implant 11970 
Areolar tattoo 11922 
    
Anesthesia 
CPT/HCPCS 
Code 
Anesthesia for procedures on anterior trunk, not otherwise specified 00400 
Anesthesia for breast reconstruction  00402 
Anesthesia for mastectomy 00404 
Anesthesia for mastectomy with node dissection 00406 
    
Hospitalizations DRG Code 
Other breast procedures without major complications 581 
Mastectomy with complications 582 
Mastectomy without complications 583 
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Table 3a 
 
      
  
   
Outline of cost model for patients with unilateral cancer    
Starting age: 45 years    
Modeling intervals: 5 years    
Only reimbursements above expected treatment for unilateral breast cancer 
included    
  
   
Group 1: Contralateral surveillance after unilateral mastectomy Baseline 
Sensitivity 
Analysis Reference 
Before Cancer Diagnosis    
Additional breast exams per year 1  36 
Number of biopsies per cancer diagnosis 4  60 
Annual percent of patients who develop CBC 0.24%  61 
Additional annual mammograms 0  35 
Additional screening MRI every two years (other breast undergoing 
implant rupture screening in between)    
  
   
After Cancer Diagnosis    
Preoperative office visits 2   
Diagnostic mammogram, basic laboratory tests    
% of patients at stage III on diagnosis: chest CT, abdominal CT, bone scan  7.40% 5% 62 
Neoadjuvant Chemotherapy: % of patients receiving it 59% 40% MGH, 63 
Neoadjuvant chemotherapy: cost per patient receiving it $6,444 $3,000 25,32 
Hopsital admission for skin-sparing contralateral mastectomy    
Lymphangiography with SLNB: % of patients receiving it 100%  MGH 
Axillary dissection for positive SLNB or clinically evident nodes: % of 
patients receiving it 10% 3%  
Immediate reconstruction with implant, expander, or DIEP    
Acellular dermal matrix for single-stage implant reconstructions    
Implant for implant and expander-based reconstructions    
Surgical pathology and immunohistochemistry    
Radiation: % of patients receiving it 38% 10% MGH, 64 
Radiation: cost per patient receiving it $5,940 $2,000 25,32,65 
Adjuvant chemotherapy: % of patients receiving it 18.2% 0% 63 
Adjuvant chemotherapy: cost assumed equal to neoadjuvant chemotherapy    
Expander reconstructions: expander to implant exchange at 6 months post-
op    
% of patients receiving NAC reconstruction and tattoo 100%   
  
   
Long-term follow-up    
Oncologist: additional visits per year for first 5 years 1  36 
Additional mammograms per year over those scheduled for prior breast 0  36 
Plastic surgeon: additional plastic surgery visits in first year 4   
Plastic surgeon: additional visits per year starting year two 0   
Follow up procedures done in ASC    
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Implant and expander reoperations in first 3 years    64,66-68 
 
% of radiated patients undergoing reoperations 45% 20%  
 
% of non-radiated patients undergoing reoperations 21% 5%  
% of patients with implants or expanders reoperated per year, starting year 
4 7.20%  69 
DIEP reoperations: radiation does not affect reoperation rate   66 
 
% of patients reoperated in year 1 34.00% 20% 67,70-73 
 
% of patients reoperated in year 2 30% 15% 67 
 
% of patients reoperated in year 3 29% 10% 67 
 
% of patients reoperated in year 4 8% 5% 67 
 
% of patients reoperated in year 5 5% 0% 67 
DIEP revision rates after year 5 0% 0%  
Implant rupture screening: additional MRI's over implant rupture 
screening for prior breast   74 
% drop in frequency of biopsies 90%  3 
  
   
Group 2: Contralateral prophylactic mastectomy at time of unilateral 
therapeutic mastectomy Baseline 
Sensitivity 
Analysis Reference 
Preoperative    
Additional preoperative office visits 1   
No additional laboratory tests    
  
   
Procedure 
 
   
Hospital admission for bilateral skin-sparing mastectomy (already 
scheduled hospitalization)    
Lymphangiography with SLNB: % of patients receiving it 100%   
Additional axillary dissection for positive SLNB or clinically evident 
nodes: % of patients receiving it 5%  12 
Immediate reconstruction with implant, expander, or DIEP    
Additional acellular dermal matrix for contralateral breast    
Additional implant for implant and expander-based reconstructions    
Surgical pathology    
Immunohistochemistry: % of patients with DCIS or cancer 7%  MGH 
Radiation: % of patients receiving it for prophylactic breast 3%  MGH 
Radiation: cost per patient receiving it $5,940 $2,000 25,32,65 
Adjuvant chemotherapy: % of patients receiving it for prophylactic breast 3.0%  MGH, 63 
Adjuvant chemotherapy: assumed equal to neoadjuvant chemotherapy    
Expander reconstructions: expander to implant exchange at 6 months post-
op    
% of patients receiving NAC reconstruction and tattoo 100%   
  
   
Long-term follow-up    
Oncologist and plastic surgeon: additional annual visits 0  MGH, 
Additional yearly mammograms 0  34 
Additional implant rupture screening MRIs 0   
Implant exchanges occur at same time as other breast    
Additional operations 0   
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Remaining long-term follow-up assumptions same as group 1    
Note: "Additional" refers to services, tests, or spending additional to what 
was already scheduled for the unilateral cancer treatment.  Any line with 
no associated reference is an assumption made for modeling.  Lines with 
MGH under the reference column represents data found in our PM 
specimens or based on a standard of care at MGH. 
   
ASC: ambulatory surgery center; CBC: contralateral breast cancer; DIEP: 
deep inferior epigastric perforator; NAC: nipple-areola complex; SLNB: 
sentinel lymph node biopsy;    
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Table 3b      
       
Outline of cost model for BRCA patients without cancer    
Starting age: 40 years    
Modeling intervals: 5 years    
       
Group 1: Bilateral surveillance Baseline 
Sensitivity 
Analysis Reference 
Before Cancer Diagnosis    
Age 25 onward: Breast exam every 6 months, annual screening 
mammogram and MRI    
Number of biopsies per cancer diagnosis 4  60 
5-year conditional probability of cancer-free BRCA patient developing 
cancer   33 
  Years 40-45 18.70%   
  Years 45-50 12%   
  Years 50-55 12%   
  Years 55-60 5.30%   
  Years 60-65 4%   
  Years 65-70 2.70%   
       
After Cancer Diagnosis    
Preoperative office visits 2   
Diagnostic mammogram, basic laboratory tests    
% of patients at stage III on diagnosis: chest CT, abdominal CT, bone scan  7.40% 5% 62 
Neoadjuvant Chemotherapy: % of patients receiving it 59% 40% MGH, 63 
Neoadjuvant chemotherapy: cost per patient receiving it $6,444 $3,000 25,32 
Hopsital admission for skin-sparing bilateral mastectomy    
Lymphangiography with SLNB: % of patients receiving it 100%  MGH 
Axillary dissection for positive SLNB or clinically evident nodes: % of 
patients receiving it 10% 3%  
Immediate reconstruction with implant, expander, or DIEP    
Acellular dermal matrix for single-stage implant reconstructions    
Implant for implant and expander-based reconstructions    
Surgical pathology and immunohistochemistry    
Radiation: % of patients receiving it 38% 10% MGH, 64 
Radiation: cost per patient receiving it $5,940 $2,000 25,32,65 
Adjuvant chemotherapy: % of patients receiving it 18.2% 0% 63 
Adjuvant chemotherapy: cost assumed equal to neoadjuvant chemotherapy    
Expander reconstructions: expander to implant exchange at 6 months post-
op    
% of patients receiving NAC reconstruction and tattoo 100%   
       
Long-term follow-up    
Oncologist: 2 annual visits first 5 years, 1 annual visit after   36 
Annual mammograms   35 
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Plastic surgeon: 4 visits in 1st year, annually thereafter    
Follow up procedures done in ASC    
Implant and expander reoperations in first 3 years    64,66-68 
  % of radiated patients undergoing reoperations 45% 20%  
  % of non-radiated patients undergoing reoperations 21% 5%  
% of patients with implants or expanders reoperated per year, starting year 
4 7.20%  69 
DIEP reoperations: radiation does not affect reoperation rate   66 
  % of patients reoperated in year 1 34.00% 20% 
67,71-
73,75,76 
  % of patients reoperated in year 2 30% 15% 67 
  % of patients reoperated in year 3 29% 10% 67 
  % of patients reoperated in year 4 8% 5% 67 
  % of patients reoperated in year 5 5% 0% 67 
DIEP revision rates after year 5 0% 0%  
Implant rupture screening: MRI every 2 years starting year 4   74 
% drop in frequency of biopsies 90%  3 
       
Group 2: Bilateral prophylactic mastectomy Baseline 
Sensitivity 
Analysis Reference 
Preoperative    
Preoperative office visits 2   
Basic laboratory test    
       
Procedure      
Hospital admission for bilateral prophylactic skin-sparing mastectomy    
Lymphangiography with SLNB: % of patients receiving it 100%   
Axillary dissection for positive SLNB or clinically evident nodes: % of 
patients receiving it 5%  12 
Immediate reconstruction with implant, expander, or DIEP    
Acellular dermal matrix for single-stage implant reconstructions    
Implant for implant and expander-based reconstructions    
Surgical pathology    
Immunohistochemistry: % of patients with DCIS or cancer 7%  MGH 
Radiation: % of patients receiving it 3%  MGH, 64 
Radiation: cost per patient receiving it $5,940 $2,000 25,32,65 
Adjuvant chemotherapy: % of patients receiving it 3.0%  MGH, 63 
Adjuvant chemotherapy: cost assumed equal to neoadjuvant chemotherapy    
Expander reconstructions: expander to implant exchange at 6 months post-
op    
% of patients receiving NAC reconstruction and tattoo 100%   
       
Long-term follow-up    
Oncologist and plastic surgeon: annual visits   MGH 
No follow-up yearly mammograms needed   MGH 
Remaining long-term follow-up assumptions same as group 1    
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Note: Any line with no associated reference is an assumption made for 
modeling.  Lines with MGH under the reference column represents data 
found in our PM specimens or based on a standard of care at MGH.ASC: 
ambulatory surgery center; CBC: contralateral breast cancer; DIEP: deep 
inferior epigastric perforator; NAC: nipple-areola complex; SLNB: sentinel 
lymph node biopsy; 
   
 ! !
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Table 4 
        Patient demographics             
  
 
CPM % BPM % Total % P-value 
Patients   377   59   436     
Age Avg. 44.8   43.4   44.6   0.203 
  SD 7.8   7.8   7.8     
  ≤ 29 5 1.3% 1 1.7% 6 1.4% 0.043 
  30-39 87 23.1% 17 28.8% 104 23.9%   
  40-49 189 50.1% 26 44.1% 215 49.3%   
  50-59 79 21.0% 14 23.7% 93 21.3%   
  ≥60 17 4.5% 1 1.7% 18 4.1%   
BRCA Pos 81 21.5% 49 83.1% 130 29.8% < 0.001 
  Neg 296 78.5% 10 16.9% 306 70.2%   
FH Yes 276 73.2% 57 96.6% 333 76.4% < 0.001 
  No 101 26.8% 2 3.4% 103 23.6%   
Prior BSO Yes 44 11.7% 30 50.8% 74 17.0% < 0.001 
  No 333 88.3% 29 49.2% 362 83.0%   
BMI Avg.  25.2 6.7% 25.1 42.7% 25.2   0.95 
  SD 4.8 1.3% 4.5 7.8% 4.7     
  <30 334 88.6% 53 89.8% 387 88.8% 0.7798 
  ≥30 43 11.4% 6 10.2% 49 11.2%   
Chemo Yes 224 59.4% 2 3.4% 226 51.8% < 0.001 
  No 153 40.6% 57 96.6% 210 48.2%   
Radiation Yes 144 38.2% 2 3.4% 146 33.5% < 0.001 
  No 233 61.8% 57 96.6% 290 66.5%   
FH: family history; Prior BSO: bilateral salpingo-oophorectomy before prophylactic 
mastectomy; BMI: body mass index; 
^ 2 prop 
Ztest 
 
 
 ! !
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Table 5 
Patients or specimens with malignant pathology (DCIS or Invasive Cancer, % with findings)   
  
 
CPM Specimens BPM Specimens Total Specimens   
Variable   Pos % Pos % Pos %   
Age ≤ 29 0 0.0% 0 0.0% 0 0.0%   
  30-39 1 1.1% 3 8.8% 4 3.3%   
  40-49 13 6.9% 2 3.8% 15 6.2%   
  50-59 9 11.4% 1 3.6% 10 9.3%   
  ≥60 3 17.6% 0 0.0% 3 15.8%   
  Total 26 6.9% 6 5.1% 32 6.5%   
  p-value 0.020   0.645 
 
0.142     
BRCA Positive 5 6.2% 4 4.1% 9 5.0%   
  
Negativ
e 21 7.1% 2 10.0% 23 7.3%   
  p-value 0.722 
 
0.268   0.328     
FH Yes 22 8.0% 6 5.3% 28 7.2%   
  No 4 4.0% 0 0.0% 4 3.8%   
  p-value 0.250   1.000   0.213     
Prior 
BSO  Yes 5 11.4% 1 1.7% 6 5.8%   
  No 21 6.3% 5 8.6% 26 6.6%   
  p-value 0.213 
 
0.111   0.746     
BMI <30 21 6.3% 6 5.7% 27 6.1%   
  ≥30 5 11.6% 0 0.0% 5 9.1%   
  p-value 0.193   0.398   0.401     
Chemo Yes 17 7.6% 1 25.0% 18 7.9%   
  No 9 5.9% 5 4.4% 14 5.2%   
  p-value 0.521   0.191   0.232     
FH: family history; Prior BSO: bilateral salpingo-oophorectomy before prophylactic mastectomy; BMI: body mass 
index; 
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Table 6 
       Patients or specimens with abnormal pathology (LCIS, DCIS, or Invasive Cancer, % with findings) 
  
 
CPM Specimens BPM Specimens Total Specimens   
Variable   Pos % Pos % Pos %   
Age ≤ 29 0 0.0% 0 0.0% 0 0.0%   
  30-39 3 3.4% 4 11.8% 7 5.8%   
  40-49 40 21.2% 4 7.7% 44 18.3%   
  50-59 24 30.4% 4 14.3% 28 26.2%   
  ≥60 6 35.3% 1 50.0% 7 36.8%   
  Total 73 19.4% 13 11.0% 86 17.4%   
  p-value < 0.001   0.407   < 0.001     
BRCA Positive 9 11.1% 7 7.1% 16 8.9%   
  Negative 64 21.6% 6 30.0% 70 22.2%   
  p-value 0.034 
 
0.003   0.019     
FH Yes 54 19.6% 13 11.4% 67 17.2%   
  No 19 18.8% 0 0.0% 19 18.1%   
  p-value 0.87   0.474   0.826     
Prior BSO  Yes 6 13.6% 2 3.3% 8 7.7%   
  No 67 20.1% 11 19.0% 78 19.9%   
  p-value 0.306 
 
0.007   0.003     
BMI <30 62 18.6% 12 11.3% 74 16.8%   
  ≥30 11 25.6% 1 8.3% 12 21.8%   
  p-value 0.273   0.754   0.356     
Chemo Yes 39 17.4% 1 25.0% 40 17.5%   
  No 34 22.2% 12 10.5% 46 17.2%   
  p-value 0.246   0.363   0.926     
FH: family history; Prior BSO: bilateral salpingo-oophorectomy before prophylactic mastectomy; BMI: body mass 
index; 
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Table&7&
! ! ! ! ! !Multivariate&analysis&by&specimen&(n=495)& ! ! !
&& DCIS&or&cancer& && LCIS,&DCIS,&or&cancer& !!
Variable& PCValue& OR& 95%&CI& PCValue& OR& 95%&CI&
Age!Group! 0.022& 1.686! 1.0702.63! <&0.001& 2.107! 1.5402.89!
BMI!≥!30! 0.317! 1.696! 0.6204.78! 0.609! 1.235! 0.5502.77!
Chemo! 0.318! 1.464! 06903.09! 0.697! 0.905! 0.5501.50!
BRCA!Status! 0.643! 0.798! 0.3102.07! 0.122! 0.586! 0.3001.15!
BSO!Status! 0.704! 0.813! 0.2802.36! 0.015& 0.34! 0.1400.81!
Family!History! 0.201! 2.041! 0.6806.10! 0.794! 1.083! 0.5901.97!
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Table&8a&
! ! ! ! !Contralateral&model&sensitivity&analysis& ! !
Growth:&
Discount&
Rates:& 0%& 0%& 3%& 7%&
0%& &Surveillance&& &Implant&& !$13,861!! !$8,563!! !$5,028!!
&& && &Expander&& !$14,048!! !$8,678!! !$5,095!!
&& && &DIEP&& !$14,080!! !$8,691!! !$5,096!!
&& &Prophylaxis&& &Implant&& !$3,856!! !$3,770!! !$3,681!!
&& && &Expander&& !$3,919!! !$3,833!! !$3,744!!
&& && &DIEP&& !$3,506!! !$3,497!! !$3,491!!
1.50%& &Surveillance&& &Implant&& !$18,093!! &$10,829&& !$6,122!!
&& && &Expander&& !$18,339!! &$10,975&& !$6,205!!
&& && &DIEP&& !$18,388!! &$10,996&& !$6,209!!
&& &Prophylaxis&& &Implant&& !$3,906!! &$3,812&& !$3,714!!
&& && &Expander&& !$3,969!! &$3,874&& !$3,776!!
&& && &DIEP&& !$3,512!! &$3,501&& !$3,493!!
3%& &Surveillance&& &Implant&& !$23,898!! !$13,861!! !$7,537!!
&& && &Expander&& !$24,222!! !$14,048!! !$7,638!!
&& && &DIEP&& !$24,295!! !$14,080!! !$7,647!!
&& &Prophylaxis&& &Implant&& !$3,962!! !$3,856!! !$3,749!!
&& && &Expander&& !$4,025!! !$3,919!! !$3,811!!
&& && &DIEP&& !$3,522!! !$3,506!! !$3,495!!
Note:!growth!denotes!annual!raise!in!prices!after!adjusting!for!inflation!
 ! !
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Table&8b&
! ! ! ! !Bilateral&model&sensitivity&analysis&& ! ! !
Growth:&
Discount&
Rates:& 0%& 0%& 3%& 7%&
0%& &Surveillance&& &Implant&& !$39,903!! !$25,829!! !$16,011!!
&& && &Expander&& !$41,153!! !$26,714!! !$16,611!!
&& && &DIEP&& !$37,542!! !$24,905!! !$15,819!!
&& &Prophylaxis&& &Implant&& !$35,679!! !$26,957!! !$21,171!!
&& && &Expander&& !$38,067!! !$29,345!! !$23,558!!
&& && &DIEP&& !$24,719!! !$21,698!! !$19,469!!
1.50%& &Surveillance&& &Implant&& !$50,862!! &$31,913&& !$19,108!!
&& && &Expander&& !$52,376!! &$32,961&& !$19,802!!
&& && &DIEP&& !$47,193!! &$30,410&& !$18,719!!
&& &Prophylaxis&& &Implant&& !$42,672!! &$30,682&& !$22,957!!
&& && &Expander&& !$45,060!! &$33,070&& !$25,345!!
&& && &DIEP&& !$27,015!! &$23,019&& !$20,192!!
3%& &Surveillance&& &Implant&& !$65,646!! !$39,903!! !$23,028!!
&& && &Expander&& !$67,497!! !$41,153!! !$23,835!!
&& && &DIEP&& !$60,041!! !$37,542!! !$22,342!!
&& &Prophylaxis&& &Implant&& !$52,279!! !$35,679!! !$25,273!!
&& && &Expander&& !$54,667!! !$38,067!! !$27,661!!
&& && &DIEP&& !$30,076!! !$24,719!! !$21,078!!
Note:!growth!denotes!annual!raise!in!prices!after!adjusting!for!inflation!
! 
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Figure 1  
 
Simplified decision tree models 
 
 
 
Two groups are considered in these models: patients with unilateral breast cancer considering 
CPM and BRCA positive patients considering BPM.  The prior model starts from age 45 and the 
latter from age 40.  At the starting point, patients choose either surveillance or PM.  Those 
choosing undergoing PM undergo surgery within the first year and receive the appropriate post-
operative follow-up.  Patients opting for surveillance in either group undergo regular screening 
as recommended by the National Comprehensive Cancer Network guidelines.  Every 5 year 
interval, a percentage of surveillance patients will remain cancer free and continue surveillance, 
whereas others will develop cancer and require therapeutic mastectomy with its appropriate 
follow-up.  Costs were modeled using both implant and DIEP reconstruction for surveillance 
patients undergoing therapeutic mastectomy and patients opting for PM.  
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Figure 2 
 
Percent of specimens with LCIS, DCIS, or cancer!!
!!
As patients age, the overall rate of each specimen having LCIS, DCIS, or cancer increases 
gradually from 0% in patients under 29 to 36.8% in patients above 60 years of age. !
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